Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison

被引：6
|
作者：
Ishak, K. Jack [1 ]
Rael, Michael [2 ]
Hicks, Meagen [3 ]
Mittal, Sangeeta [3 ]
Eatock, Martin [4 ]
Valle, Juan W. [5 ,6 ]
机构：
[1] Evidera Inc, Montreal, PQ, Canada
[2] Evidera Inc, San Francisco, CA 94111 USA
[3] Pfizer Ltd, Walton Oaks, Surrey, England
[4] Belfast City Hosp, Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland
[5] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 10期
关键词：
comparative effectiveness; everolimus; MAIC; matching-adjusted indirect comparison; sunitinib;
D O I：
10.2217/cer-2018-0020
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111). Methods: The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus. Results: The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS. Conclusion: Findings indicate comparable PFS and OS with sunitinib and everolimus.
引用
收藏
页码：947 / 958
页数：12
相关论文
共 50 条
  • [31] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
    Armstrong, April W.
    Park, Sang Hee
    Patel, Vardhaman
    Hogan, Malcolm
    Wang, Wei-Jhih
    Davidson, David
    Chirikov, Viktor
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2589 - 2603
  • [32] Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
    Swallow, Elyse
    Song, Jinlin
    Yuan, Yong
    Kalsekar, Anupama
    Kelley, Caroline
    Peeples, Miranda
    Mu, Fan
    Ackerman, Peter
    Signorovitch, James
    CLINICAL THERAPEUTICS, 2016, 38 (02) : 404 - 412
  • [33] Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China
    Liu, Ying
    He, Xiaoning
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [34] Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison
    Atkins, Michael B.
    Tarhini, Ahmad
    Rael, Michael
    Gupte-Singh, Komal
    O'Brien, Elliott
    Ritchings, Corey
    Rao, Sumati
    McDermott, David F.
    IMMUNOTHERAPY, 2019, 11 (07) : 617 - 629
  • [35] A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 660 - 668
  • [36] Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Tombal, B.
    Sternberg, C. N.
    Hussain, M.
    Ganguli, A.
    Li, Y.
    Sandin, R.
    Bhadauria, H.
    Oh, M.
    Saad, F.
    ESMO OPEN, 2022, 7 (03)
  • [37] Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life
    Ion Agirrezabal
    Victoria K. Brennan
    Fabien Colaone
    Suki Shergill
    Helena Pereira
    Gilles Chatellier
    Valérie Vilgrain
    Advances in Therapy, 2022, 39 : 2035 - 2051
  • [38] Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
    Maksymowych, Walter P.
    Thom, Howard
    Morup, Michael F.
    Taieb, Vanessa
    Willems, Damon
    Lyris, Nikos
    Gaffney, Karl
    RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 1023 - 1041
  • [39] Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
    Paik, Paul K.
    Pfeiffer, Boris M.
    Vioix, Helene
    Garcia, Andrea
    Postma, Maarten J.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3159 - 3179
  • [40] Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
    Paul K. Paik
    Boris M. Pfeiffer
    Helene Vioix
    Andrea Garcia
    Maarten J. Postma
    Advances in Therapy, 2022, 39 : 3159 - 3179
12345